Mirati Therapeutics, a clinical-stage oncology company, focuses on the research and development of novel therapeutics targeting the genetic and immunological drivers of cancer
Mirati Therapeutics, a clinical-stage oncology company, focuses on the research and development of novel therapeutics targeting the genetic and immunological drivers of cancer. Their product pipeline includes inhibitors for KRAS mutations, specifically for colorectal and pancreatic cancers.